)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
CG Oncology
CG Oncology (CGON) investor relations material
CG Oncology TD Cowen 46th Annual Health Care Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.TD Cowen 46th Annual Health Care Conference summary2 Mar, 2026
Clinical trial updates and efficacy data
BOND-003 trial shows a 75.5% CR rate at any time and 46.4% at 12 months in over 110 patients, with 90% maintaining CR at 2 years, outperforming competitors.
Credo demonstrates promising results as adjuvant therapy in papillary disease and is being evaluated in multiple cohorts, including BCG-naive and intermediate-risk populations.
PIVOT-006 trial uniquely includes high-grade Ta lesions and aims for recurrence-free survival, with top-line data expected this year.
Combination studies with gemcitabine and prior work with pembrolizumab show potential for enhanced response rates.
Early data in BCG-naive patients show an 88% complete response rate in the optimized cohort.
Regulatory and commercialization plans
BLA submission for high-risk indication has begun, with completion targeted for 2026 and intermediate-risk filing expected in 2027.
Manufacturing and CMC processes are a primary focus, especially fill-finish facility validation and readiness for FDA inspection.
Commercial launch preparations include a specialized sales and medical team, targeting a concentrated market of about 300 key accounts.
Pricing is based on dose intensity, with 30 doses over 3 years for high-risk and 14 doses over 1 year for intermediate-risk, aligning with current reimbursement models.
Market opportunity is considered significant, with multi-billion dollar potential across indications, but penetration and persistence on therapy will determine realized value.
Competitive positioning and strategic insights
Credo’s durability of response and safety profile are highlighted as key differentiators, especially compared to competitors like Keytruda and TAR-200.
Launch strategy incorporates learnings from recent market entrants, focusing on prescriber behavior, access, and formulary adoption timelines.
The product is positioned as a first-choice therapy for BCG-unresponsive disease, with a two-year lead in the adjuvant setting over other branded products.
Upcoming catalysts include additional data readouts from ongoing trials and further guidance on regulatory timelines.
The team leverages a strong track record in bladder cancer and is actively expanding commercial infrastructure.
How does new FDA flexibility impact BLA timeline?
How will Credo achieve 'first choice' in a concentrated market?
How does dose intensity affect market value per indication?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next CG Oncology earnings date
Q1 202612 May, 2026
CG Oncology
Next CG Oncology earnings date
Q1 202612 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
CG Oncology Inc. is a late-stage clinical biopharmaceutical company primarily engaged in the development and commercialization of innovative treatments for bladder cancer. The company's main focus is on creating a bladder-sparing therapeutic option for patients suffering from this disease. CG Oncology's leading product candidate, cretostimogene, is currently in clinical development targeting high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) patients who have not responded to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care. The company is headquartered in Irving, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage